Immutep Limited Securities Class Action

Class Period

March 24, 2025 - March 12, 2026

Motion Deadline

July 6, 2026|57 days left

Please submit the form below if you believe you have incurred losses.

First Name *

Last Name *

Email Address *

Phone *

Address Line 1

City

State / Province / Region

Postal Code

Country

Investment Details

Estimated Losses *

Do you still retain shares?

Transactions Information

Select a file or drag and drop here

PDF, XLS, or CSV, file size no more than 25MB

Additional information

By clicking the submit button above, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Pomerantz LLP ("Pomerantz" or "The Firm"), and that the submission or receipt of information to the Firm or one of its attorneys via this form, website, e-mail or telephone does not create an attorney-client relationship. Prior results do not guarantee a similar outcome in future cases.

Pomerantz LLP does not share your information with others. There is no cost or obligation for you to submit. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases.

Allegations

On March 13, 2026, Immutep issued a press release “announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (‘efti’) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol.” According to the press release, “[b]ased on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility” and that, accordingly, “enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations.” On this news, Immutep’s American Depositary Receipt (“ADR”) price fell $2.27 per ADR, or 82.44%, to close at $0.48 per ADR on March 13, 2026.

Lead Plaintiff

If you have qualifying losses, you may be eligible to serve as Lead Plaintiff. Acting as a representative for all class members seeking recovery in the lawsuit, the Lead Plaintiff plays an important role in the litigation, including selecting a law firm to serve as Lead Counsel and approving the final settlement. There is no cost whatsoever to seek or participate as a Lead Plaintiff. The Lead Plaintiff may also receive a monetary award for their participation in the suit.

About the Firm

Founded in 1936, Pomerantz LLP is the oldest law firm in the world dedicated to championing investor rights. Throughout its history, the Firm has won landmark decisions that have initiated historic corporate governance reforms and shaped the law to better protect shareholders. Pomerantz has successfully resolved hundreds of securities class actions as Lead Counsel, recovering billions of dollars on behalf of defrauded investors with many settlements breaking previously held records. Pomerantz is headquartered in New York City, with offices in Los Angeles, Chicago, Paris, London, and Tel Aviv.